RxDoctor Payments Data

Katherine Ludington, MD

Cardiovascular Disease · Encinitas, CANPI 1164420469

Payments from drug & device makers

$500,031in general payments, 2019–2025

Across 434 payments — averaging $1152.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$271K
  • Alnylam Pharmaceuticals Inc.$198K
  • AstraZeneca$23K
  • Biotronik Inc.$2K
  • Impulse Dynamics (USA) Inc.$1K
  • Medtronic$1K
  • plus $4K from 38 others
$93,288in research payments, 2019–2025

Across 3 payments — averaging $31,096 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$93K

What the payments were for

  • Food & beverage$8,014100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$500,031 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,534,519
Medicare patients
864
Services billed
13,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban245$322,649
XareltoRivaroxaban90$129,539
Repatha SureclickEvolocumab41$49,103
Praluent PenAlirocumab64$46,972
LivaloPitavastatin Calcium24$18,750
EntrestoSacubitril/Valsartan16$15,870
MounjaroTirzepatide11$12,364
Rosuvastatin Calcium535$8,383
Metoprolol Succinate361$6,769
Propafenone Hcl ErPropafenone Hcl21$5,858
Pitavastatin Calcium30$5,379
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide122$4,564
Ezetimibe107$4,170
Valsartan110$3,591
Potassium Chloride86$3,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$375$322,649245 claims
Johnson & JohnsonXarelto$97$129,53990 claims
Kowa Pharmaceuticals America, Inc.Livalo$182$18,75024 claims
NovartisEntresto$175$15,87016 claims
Lilly USA, LLCMounjaro$71$12,36411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →